Impacts of antibiotic and anti-inflammatory therapies on serum prostate-specific antigen levels in the presence of prostatic inflammation: A prospective randomized controlled trial

Urologia Internationalis

Volumn 84, Issue 2, 2010, Pages 185-190

  Ugurlu, Ozgur ^a   Yaris, Mehmet ^a   Oztekin, C Volkan ^a   Kosan, T Murat ^a   Adsan, Oztug ^a   Cetinkaya, Mesut ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Anti inflammatory agents; Antibacterial therapy; Prostate biopsy; Prostate inflammation; Prostate specific antigen

Indexed keywords

LEVOFLOXACIN; NAPROXEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DRUG EFFECT; DRUG USE; EMPIRICISM; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE INFLAMMATION; PROSTATE SECRETION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BIOPSY; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATITIS; SAMPLE SIZE;

EID: 77949388483     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000277596     Document Type: Article

References (24)

1. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-923.
2. Catalona WJ, Ramos CG, Carvalhal GF, et al: Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 2000; 55: 791-795.
3. Gilbert SM, Cavallo CB, Kahane H, Lowe FC: Evidence suggesting PSA cutpoint of 2.5 ng/ ml for prompting prostate biopsy: review of 26,316 biopsies. Urology 2005; 65: 549-553.
4. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154: 407-413.
5. Kravchick S, Cytron S, Agulansky L, Ben-Dor D: Acute prostatitis in middle-aged men: a prospective study. BJU Int 2004; 93: 93-96.
6. Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith DS, Catalona WJ: Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 1992; 147: 810-814.
7. Neal DE Jr, Clejan S, Sarma D, Moon TD: Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate 1992; 20: 105-111.
8. Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J: Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 1997; 157: 1301-1304.
9. Carver BS, Bozeman CB, Williams BJ, Venable DD: The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. J Urol 2003; 169: 589-591.
10. Potts J: Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. J Urol 2000; 164: 1550-1553.
11. Karazanashvilii G, Managadze L: Prostatespecific antigen value change after antibacterial therapy of prostate inflammation, as a diagnostic method for prostate cancer screening in cases of PSA value within 4-10 ng/ml and nonsuspicious results of digital rectal examination. Eur Urol 2001; 39: 538-543.
12. Bozeman CB, Carver BS, Eastham JA, Verable DD: Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol 2002; 167: 1723-1726.
13. Kaygisiz O, Ugurlu O, Kosan M, Inal G, Ozturk B, Cetinkaya M: Effects of antibacterial therapy on PSA change in the presence and absence of prostatic inflammation in patients with PSA levels between 4 and 10 ng/ ml. Prostate Cancer Prostatic Dis 2006; 9: 235-238.
14. Eastham JA, Riedel E, Scardino PT: Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003; 289: 2695-2700.
15. Wright ET, Chmiel JS, Grayhack JT, Schaeffer AJ: Prostate fluid inflammation in prostatitis. J Urol 1994; 152: 2300-2303.
16. Sölétormos G, Semjonow A, Sibley PE, Lamerz R, Petersen PH, Albrecht W, et al: Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005; 51: 1342-1351.
17. Kobayashi M, Nukui A, Morita T: Serum PSA and percent free PSA value changes after antibiotic treatment: a diagnostic method in prostate cancer suspects with asymptomatic prostatitis. Urol Int 2008; 80: 186-192.
18. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS: Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol 2007; 178: 896-901.
19. Schaeffer AJ, Knauss JS, Landis JR: Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study. J Urol 2002; 168: 1048-1053.
20. Brawn PN, Speights VO, Kuhl D, et al: Prostate-specific antigen levels from completely sectioned, clinically benign whole prostates. Cancer 1991; 68: 1592-1599.
21. Tugcu V, Tasci AI, Fazlioglu A, et al: A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). Eur Urol 2007; 51: 1113-1118.
22. Basler JW, Piazza GA: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 2004; 171: 59-63.
23. Roberts RO, Lieber MM, Bostwick DG, Jacobsen SJ: A review of clinical and pathological prostatitis syndromes. Urology 1997; 49: 809-821.
24. Doble A: Chronic prostatitis. Br J Urol 1994; 74: 537-541.